


# Genetic Risk Assessment for Cancer

Jennifer Siettmann, MS CGC

Certified Genetic Counselor  
Banner MD Anderson Cancer  
Center



Banner MD Anderson  
~~Cancer~~ Center  
Making Cancer History®




# Objectives




- Describe the role of genetic counseling and genetic testing in patient care
- List indications for referral for hereditary cancer genetic testing
- Describe features of common hereditary cancer syndromes
- Describe the genetic testing process and new testing advancements

# Genetic Predisposition Testing is a Multistep Process



# How Much Cancer is Hereditary?



## Hereditary

- Gene mutation is inherited in family
- Significantly increased cancer risk

## Familial

- Multiple genes & environmental factors may be involved
- Some increase in cancer risk

## Sporadic

- Cancer occurs by chance or related to environmental factors
- General population cancer risk



# When to Expect a Hereditary Cancer Syndrome




- Cancer in two or more close relatives (on same side of family)
- Early age at diagnosis (<50)
- Multiple primary tumors in the same individual
- Bilaterality or multiple rare cancers
- Pattern of tumors consistent with specific cancer syndrome (e.g. breast *and* ovary)
- Evidence of autosomal dominant transmission
  - Multiple affected generations
- Presence of congenital anomalies or syndrome-associated benign lesions

Lindor NM et al. *J Natl Cancer Inst.* 1998;90:1039-1071.

Schneider K. *Counseling About Cancer: Strategies for Genetic Counseling.* 2nd ed. New York: John Wiley & Sons; 2001.



# Suspicious Genetic Cancers



# Hereditary Cancer Syndromes



- Breast
  - Hereditary Breast and Ovarian Cancer Syndrome (BRCA1, BRCA2)
  - Cowden (PTEN)
  - Hereditary Diffuse Gastric Cancer (CDH1)
  - Li Fraumeni Syndrome (TP53)
  - PALB2
  - Moderate Risk Syndromes (ATM, CHEK2, NBN, NF1)
- Ovarian
  - Moderate Risk Syndromes (RAD51C, RAD51D, BRIP1)
- Colon
  - Lynch Syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM)
  - Familial Adenomatous Polyposis (FAP)
  - MUTYH Associated Polyposis (MAP)
  - Peutz-Jeghers Syndrome (STK11)
  - Juvenile Polyposis Syndrome (SMAD4, BMPR1A)
  - Moderate Risk Syndromes (GREM1, POLD1, POLE)

# Hereditary Cancer Syndromes



- Endocrine
  - Multiple Endocrine Neoplasia Type I (MEN1)
  - Multiple Endocrine Neoplasia Type II (RET)
  - Hereditary Paraganglioma and Pheochromocytoma (SDH1, SDHAF2, SDHC, SDHD, MAX, TMEM127)
- Melanoma
  - Hereditary Malignant Melanoma (CDK4, CDKN2A)
  - BAP1 Associated Hereditary Melanoma (BAP1)
- Renal
  - Von Hippel Lindau (VHL)
  - Hereditary Leiomyomatosis and Renal Cell Cancer (FH)
  - Birt-Hogg Dube Syndrome (FLCN)
  - Tuberous Sclerosis Complex (TSC1, TSC2)
  - Moderate Risk Syndromes (MET, MITF)



# Rare Tumors That Warrant Genetic Evaluation




- Adrenocortical Carcinoma (*Tp53*)
- Carcinoid Tumors (specifically thymic gland) (*MEN1*)
- Diffuse Gastric Cancer (*CDH1*)
- Fallopian Tube/Primary Peritoneal Cancer (*BRCA1/BRCA2*)
- Leiomyosarcoma (*FH*)
- Medullary Thyroid Cancer (*RET*)
- Paraganglioma (*SDHA, SDHB, SDHC, SDHD, SDHAF2*)
- Pheochromocytoma (*SDHA, SDHB, SDHC, SDHD, SDHAF2, VHL, RET, NF1*)
- Chromophobe or Oncocytic Renal Cell Cancer (*FLCN*)
- Sebaceous Neoplasms/Carcinomas (*MLH1, MSH2, MSH6, PMS2, EPCAM*)
- Sex Cord Tumors with Annular Tubules (*STK11*)

# Hereditary Breast and Ovarian Cancer Syndrome (HBOC)



- Caused by mutations in the *BRCA1* and *BRCA2* tumor suppressor genes
- Incidence: 1 in 4,000
  - 1 in 40 in Ashkenazi Jewish families
- Features:
  - Early onset breast cancer (under age 50)
  - Ovarian cancer
  - Bilateral breast cancer
  - Male breast cancer
  - Ashkenazi Jewish heritage

# HBOC Lifetime Cancer Risks



Breast cancer: 50-85%  
(often early age at onset)

Second primary breast cancer: 40-60%  
(5%/yr vs. 1%/yr for sporadic BC)

Ovarian cancer: 15-45%

Absolute risk likely to be higher than 10%

\*Prostate cancer

Absolute risk 10% or lower

\*Male breast cancer

\*Fallopian tube cancer

\*Pancreatic cancer

Begg CB. *J Natl Cancer Inst.* 2002;94:1221-1226.

Breast Cancer Linkage Consortium. *J Natl Cancer Inst.* 1999;91:1310-1316.

Ford D et al. *Am J Hum Genet.* 1998;62:676-689.

# Lynch Syndrome



- Caused by mutations in mismatch repair genes *MLH1*, *MSH2*, *MSH6*, and *PMS2*
- Features:
  - Early age of colon cancer diagnosis (~45 years)
  - Right-sided cancers
  - Cancers outside the colon:
    - Uterine/Endometrial
    - Ovarian
    - Stomach, small bowel, urinary tract, bile ducts, brain, pancreas



# Lynch Syndrome Lifetime Cancer Risks



	General Population	MLH1 and MSH2 Mutation	MSH6 Mutation	PMS2 Mutation
Colon	5.5%	40-80%	10-22%	15-20%
Endometrial	2.7%	25-60%	16-26%	15%
Stomach	<1%	1-13%	≤3%	Combined Risk of 6%
Ovarian	1.6%	4-24%	1-11%	
Bile Duct	<1%	1.4-4%	Not reported	
Urinary Tract	<1%	1-4%	<1%	
Small Bowel	<1%	3-6%	Not reported	
Brain/CNS	<1%	1-3%	Not reported	
Sebaceous neoplasms	<1%	1-9%	Not reported	Not reported
Pancreas	<1%	1-6%	Not reported	Not reported

# IHC Testing for Lynch Syndrome




MLHI 


MSH6 

MSH2 

PMS2 




Normal



Suspicious of Lynch

# Genetic Predisposition Testing is a Multistep Process



# Pretest Genetic Counseling



- Assess
  - Personal and family medical history
  - Risk perception and motivation for testing
- Educate
  - Basic genetics and inheritance
  - Cancer genetics and risk
- Discuss
  - Risks, benefits, and limitations of testing
  - Test procedure
  - Alternatives to testing
  - Management options
- Counsel
  - Provide anticipatory guidance
  - Walk them through “what if” scenarios
  - Support them

Lerman C et al. *J Natl Cancer Inst.* 1997;89:148-175.


Masood E. *Nature.* 1996;379:389-392.



Banner MD Anderson  
Cancer Center  
Making Cancer History®




# Creating a Family History or Pedigree




□ ○	Male, female	▢ ○	Mutation carrier
↗ ↘	Proband (patient initiating genetic workup)	■ ●	Affected with trait
⊘ ⊘	Deceased	⊠	Adopted
□ ○	Mating	⊎	Dizygotic twins
○ □ ○	Sibship	⊎	Monozygotic twins

# Basic Genetics




# Inheritance: Typically Autosomal Dominant



© Clinical Tools, Inc.

# Genetic Predisposition Testing is a Multistep Process





# Genetic Testing Options



- **Single-Site Testing**
  - known BRCA mutation in family
- **Single Gene Testing**
  - (TP53)
- **Single Syndrome Testing**
  - (BRCA1, BRCA2)
- **High Risk Breast Panel**
  - (BRCA1, BRCA2, CDH1, PALB2, PTEN, TP53)
- **Guidelines-Based Breast Panel**
  - (ATM, BRCA1, BRCA2, CDH1, CHEK2, PALB2, PTEN, TP53)
- **Expanded Breast Panel**
  - (17+ genes)
- **Pan-Cancer Panel**
  - ex. CancerNext (32+ genes)
- **Pan-Cancer Expanded Panels**
  - (40+ genes)



# Important Considerations




- Insurance Coverage/Price
  - Insurances requiring to meet with ‘genetic expert’
  - Cost ranges from ~\$250-\$4,000 OOP
  - Insurance has a “one time only” policy on testing
- Turnaround Time
  - 1 – 3 weeks
- Correct Test for Indication
  - Pan Cancer Panels vs. Single Cancer Panel
- Possible Results
  - Positive vs. Negative vs. Variants
- High vs. Low Risk Genes
  - Future management?

# Genetic Testing Labs




DISEASE PREVENTION THROUGH GENETIC TESTING

# Genetic Predisposition Testing is a Multistep Process




# Understanding Possible Test Results






# High-Risk Clinical Management



# Genetic Predisposition Testing is a Multistep Process



# Genetic Discrimination



- In 2008, a federal law called the Genetic Information Nondiscrimination Act (GINA) was passed
  - Prevents health insurance and employers from discriminating based on genetic test results
  - Doesn't apply to life insurance or long-term disability
  - Doesn't apply to the military

## Quick Guide to GINA

### What GINA does

- Prohibits group and individual health insurers from using a person's genetic information in determining eligibility or premiums
- Prohibits an insurer from requesting or requiring that a person undergo a genetic test
- Prohibits employers from using a person's genetic information in making employment decisions such as hiring, firing, job assignments, or any other terms of employment
- Prohibits employers from requesting, requiring, or purchasing genetic information about persons or their family members
- Will be enforced by the Department of Health and Human Services, the Department of Labor, and the Department of Treasury, along with the Equal Opportunity Employment Commission; remedies for violations include corrective action and monetary penalties

### What GINA does not do

- Does not prevent health care providers from recommending genetic tests to their patients
- Does not mandate coverage for any particular test or treatment
- Does not prohibit medical underwriting based on current health status
- Does not cover life, disability, or long-term-care insurance
- Does not apply to members of the military

### Key terms

"Genetic information" includes information about:

- A person's genetic tests
- Genetic tests of a person's family members (up to and including fourth-degree relatives)
- Any manifestation of a disease or disorder in a family member
- Participation of a person or family member in research that includes genetic testing, counseling, or education

"Genetic tests" refers to tests that assess genotypes, mutations, or chromosomal changes

Examples of protected tests are:

- Tests for *BRCA1/BRCA2* (breast cancer) or *HNPCC* (colon cancer) mutations
- Classifications of genetic properties of an existing tumor to help determine therapy
- Tests for Huntington's disease mutations
- Carrier screening for disorders such as cystic fibrosis, sickle cell anemia, spinal muscular atrophy, and the fragile X syndrome

Routine tests such as complete blood counts, cholesterol tests, and liver-function tests are not protected under GINA

# Referral to a Genetic Counselor



- Before Testing
  - Patient meeting these criteria:
    - Breast cancer <50
    - Any triple negative breast cancer
    - 2+ breast cancer in the family
    - Ovarian cancer in patient or family
    - Breast and pancreatic cancer
    - Uterine or colon cancer under age 50
    - Patients with multiple types of cancer
    - Patients with significant family history of cancer not fitting typical pattern
  - Questions about which panel to order
  - Patients with insurances requesting genetic counseling
  - Patients with large out-of-pocket cost for testing

# Referral to a Genetic Counselor



- After Testing
  - Any patient with:
    - Positive test result
    - Variant of uncertain significance
    - Negative test report but significant family history
    - Additional questions

You are always welcome to contact any of us with any questions or concerns!



# Case Example 1: KM




- KM breast cancer @ 47
  - Mother: Br.Ca @ 28  
Died of Ov. Ca. @ 37
  - Maternal Aunt: Br. Ca @ 50
  - Maternal Aunt: Br. Ca. @ 58
  - Maternal Grandma: Br. Ca died in 50s
  - Father: Lung Ca @ 73
  
- European descent both sides






European

non AJ

European



 Diagnosis = Br
  Diagnosis = Lung
  Diagnosis 2 = Ov

# Case 1: KM Test Results and Plan







- Ordered a panel of 17 breast cancer genes
- Test Result:
  - Positive for a *BRCA2* mutation
    - Up to 85% risk for breast cancer
      - 60% Risk for second primary
    - Up to 40% risk for ovarian/fallopian tube cancer
    - 6% risk for Male breast cancer
- Prevention Method
  - Bilateral salpingo-oophorectomy
  - Bilateral mastectomy
- Family Prevention
  - Offer testing and high risk prevention options to all close family members

European

non AJ

European



 Diagnosis = Br 
  Diagnosis = Lung 
  Diagnosis 2 = Ovr


# Case Example 2: PA



- PA is a 65 y.o. woman diagnosed with uterine cancer @ 61 and bladder cancer @ 65
  - Sister: pancreatic @ 64
  - Mom: colon @ 56
  - Maternal aunt: colon @ 89
  - Maternal aunt: ovarian
  - Maternal cousin: colon in 40s
- European descent on both sides







# Case 2: PA Test Results and Plan




- Ordered a panel for 32 cancer genes
- Test Result:
  - Positive for a *MSH6* mutation
    - Up to 22% risk for colon cancer
    - Up to 26% risk for uterine cancer
    - Up to 11% risk for ovarian cancer
    - Increased risk for stomach, urinary tract, and possibly breast cancers
  - Variant of uncertain significance (VUS) in *NBN*
    - True mutations associated with moderately increased risk for breast and ovarian cancer
- Prevention Method:
  - Colonoscopy every 1-2 years beginning age 25-30
  - Patient already had hysterectomy and bilateral salpingo-oophorectomy
  - No screening is recommended for the *NBN* VUS as it is an inconclusive result and we cannot make recommendations for an inconclusive result
- Family Prevention:
  - Offer testing and high risk prevention options to all close family members

# Case Example 3: BB



- BB diagnosed with breast cancer @ 49
  - Mother: breast @ 76
  - Maternal aunt: breast @ 44
  - 2 maternal uncles: brain @ 56 and 64
  - Paternal aunt: breast
  - Paternal cousin: breast @ 44
  - Paternal grandma: breast @ 31
- European descent on both sides






- Diagnosis = Brain
- Diagnosis = Pr
- Diagnosis = Brain
- Diagnosis = DCIS
- Diagnosis 2 = Skin-NOS
- Diagnosis = Br

# Case 3: CD Test Results and Plan



- Ordered a panel for 17 breast cancer genes
- Test Result:
  - Positive for a *Tp53* mutation, responsible for Li Fraumeni Syndrome
    - 50% risk for any type of cancer by age 40
    - 90% risk for any type of cancer by age 60





# Case 3: CD Test Results and Plan



- Prevention Method

Cancer	0-1 Years
General	Biannual physical exam (neurological, thyroid) Avoid radiation treatment when possible
Adrenocortical and Sarcoma	Annual Testosterone levels
	Annual WB-MRI*
Brain	Annual brain MRI*
Leukemia	Annual CBC, Erythrocyte labs
Melanoma	Annual dermatologic exam
Breast (begin at 25)	Biannual clinical breast exam
	Annual MRI and mammogram
	Consider prophylactic mastectomy
Colon (begin at 25)	Colonoscopy and upper endoscopy every 2-5 years
Ovarian (begin at 35)	Biannual CA-125 and transvaginal U/S
	Consider removing ovaries and uterus

# Questions?

phone: 480-256-3642

[jennifer.siettmann@bannerhealth.com](mailto:jennifer.siettmann@bannerhealth.com)

